prof. Ján Pečeňák, MD, PhD.
Research/art/teacher profile of a person
The most significant research/artistic/other outputs:
1. | Karagianis J, Novick D, Pecenak J, Haro JM, Dossenbach M, Treuer T, Montgomery W, Walton R, Lowry AJ. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. International Journal of Clinical Practice. 2009 | Q1 | IF 2,245 |
2. | Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Current Medical Research and Opinion. 2010 | Q1 | IF 2,609 |
3. | Pecenak J, Novotny V. Agomelatine as monotherapy for major depression: an outpatient, open-label study. Neuropsychiatric Disease and Treatment. 2013 | Q2 | IF 2,154 |
4. | Ondicova K, Tillinger A, Pecenak J, Mravec B. The vagus nerve role in antidepressants action: Efferent vagal pathways participate in peripheral anti-inflammatory effect of fluoxetine. Neurochemistry International. 2019 | Q2 | IF 3,881 |
5. | Kiss A, Koprdova R, Osacka J, Pecenak J. c-Fos expression response to olanzapine, amisulpride, aripiprazole, and quetiapine single administration in the rat forebrain: Effect of a mild stress preconditioning. Neurochem Int. 2019 | Q2 | IF 3,881 |